Ireland· IE-PA-EU/1/13/822/001
PHEBURANE 483 mg/g granules
A sodium phenylbutyrate product containing sodium 4-phenylbutyrate, registered in Ireland by Eurocept International BV. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Sodium phenylbutyrate is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AX03 (sodium phenylbutyrate), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Sodium phenylbutyrate · ATC A16AX03
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sodium phenylbutyrate costs, country by country.
Normalised to the WHO defined daily dose (20 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sodium phenylbutyrate · price per daily dose (20 g)
USD · FX 28 Sept 2026
- CZ Czechia$0.46
The record
At a glance
HPRA (Ireland)- Active substance
- Sodium 4-phenylbutyrate
- Manufacturer
- Eurocept International BV
- Country
- Ireland (IE)
- ATC code
- A16AX03
- ATC class
- Sodium phenylbutyrate
- Defined daily dose
- 20 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/13/822/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under A16AX03
Sodium phenylbutyrate, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cbf56f34-64e2-40a9-aab1-feefd5efcdad GET /v1/drugs/cbf56f34-64e2-40a9-aab1-feefd5efcdad?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Granules",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A16AX",
"A16AX03"
],
"strength": null,
"pa_number": "EU/1/13/822/001",
"substances": [
"Sodium 4-phenylbutyrate"
],
"legal_basis": "Hybrid application (Article 10(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "31/07/2013",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about sodium phenylbutyrate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.